Summary

The global hyperphosphatemia drugs market size reached USD 4.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.2 Billion by 2033, exhibiting a growth rate (CAGR) of 6.72% during 2025-2033. The rising prevalence of end stage kidney disease (ESKD), considerable rise in the geriatric population that is susceptible to developing chronic ailments and the increasing health consciousness resulting in the rising trend of early disease diagnosis represent some of the key factors driving the market.

Hyperphosphatemia is characterized by an elevated level of phosphate in the blood as a result of increased intake of phosphate, migration of phosphate out of the cells, and decreased excretion of phosphate. Hyperphosphatemia is frequently found in people who suffer from chronic kidney diseases, diabetic ketoacidosis, uncontrolled diabetes, and low parathyroid hormone levels. Medications for hyperphosphatemia, which tend to contain phosphate binders, help control the high levels of phosphate in the blood. Additionally, hyperphosphatemia drugs are effective at reducing phosphorus absorption through the gastrointestinal tract. They exchange an anion phosphate with an active cation, such as carbonate, acetate, oxyhydroxide, or citrate, to form a compound that is nonabsorbable and excreted.

Hyperphosphatemia Drugs Market Trends:
The rising prevalence of various chronic diseases, particularly end stage kidney disease (ESKD), across the globe is a significant factor driving the growth of the market. This can be attributed to a considerable rise in the geriatric population that is susceptible to developing these ailments. In line with this, the increasing number of product launches due to the approval of novel drugs are positively impacting the market. Also, the introduction of strong pipeline drugs in numerous clinical trials is creating lucrative growth opportunities in the market. However, the growing side effects of hyperphosphatemia drugs, the rising stringency in regulations by the drug-governing bodies in several countries, and high production costs are restraining the market growth. On the contrary, extensive research and development (R&D) activities in drug manufacturing procedures are creating a positive outlook for the market. Apart from this, a significant increase in collaborations, partnerships and strategic merger and acquisition (M&As) by the key players to extend their geographical presence is also providing an impetus to the market. The market is further fueled by the shifting preference toward the adoption of non-phosphate binder drugs from the conventional phosphate binder drugs. Moreover, the increasing medical expenditure, along with continual technological improvements in the healthcare infrastructure facilities, are propelling the market. Some of the other factors contributing to the market include rapid urbanization, product premiumization, the rising trend of early disease diagnosis, considerable growth in the biotechnology industry and inflating disposable income levels.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global hyperphosphatemia drugs market, along with forecasts at the global, regional, and country level from 2025-2033. Our report has categorized the market based on product, dosage form, and distribution channel.

Product Insights:

Sevelamer
Calcium Based Phosphate Binders
Iron Based Phosphate Binders
Lanthanum Carbonate
Others

The report has provided a detailed breakup and analysis of the hyperphosphatemia drugs market based on the product. This includes sevelamer, calcium based phosphate binders, iron based phosphate binders, lanthanum carbonate, and others. According to the report, sevelamer represented the largest segment.

Dosage Form Insights:

Tablets
Syrups
Capsules

The report has provided a detailed breakup and analysis of the hyperphosphatemia drugs market based on the dosage form. This includes tablets, syrups, and capsules. According to the report, tablets represented the largest segment.

Distribution Channel Insights:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

A detailed breakup and analysis of the hyperphosphatemia drugs market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, and online pharmacies. According to the report, hospital pharmacies accounted for the largest market share.

Regional Insights:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for hyperphosphatemia drugs. Some of the factors driving the North America hyperphosphatemia drugs market include the increasing number of product launches due to the approval of novel drugs, extensive research and development (R&D) activities conducted by key players, and the growing medical expenditure, along with continual technological improvements in healthcare infrastructure facilities.

Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global hyperphosphatemia drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Ardelyx Inc., Fresenius Medical Care AG & Co. KGaA, Lupin Pharmaceuticals Inc (Lupin Limited), Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.), Vifor Pharma Management Ltd. (CSL Limited), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:
How has the global hyperphosphatemia drugs market performed so far and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global hyperphosphatemia drugs market?
What are the key regional markets?
Which countries represent the most attractive hyperphosphatemia drugs markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the dosage form?
What is the breakup of the market based on the distribution channel?
What is the competitive structure of the global hyperphosphatemia drugs market?
Who are the key players/companies in the global hyperphosphatemia drugs market?

ページTOPに戻る

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Hyperphosphatemia Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Product
6.1 Sevelamer
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Calcium Based Phosphate Binders
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Iron Based Phosphate Binders
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Lanthanum Carbonate
6.4.1 Market Trends
6.4.2 Market Forecast
6.5 Others
6.5.1 Market Trends
6.5.2 Market Forecast
7 Market Breakup by Dosage Form
7.1 Tablets
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Syrups
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Capsules
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Distribution Channel
8.1 Hospital Pharmacies
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Retail Pharmacies
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Online Pharmacies
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 Drivers, Restraints, and Opportunities
10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 Ardelyx Inc.
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.2 Fresenius Medical Care AG & Co. KGaA
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Lupin Pharmaceuticals Inc (Lupin Limited)
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.)
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.5 Vifor Pharma Management Ltd. (CSL Limited)
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

List of Figures

Figure 1: Global: Hyperphosphatemia Drugs Market: Major Drivers and Challenges
Figure 2: Global: Hyperphosphatemia Drugs Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 4: Global: Hyperphosphatemia Drugs Market: Breakup by Product (in %), 2024
Figure 5: Global: Hyperphosphatemia Drugs Market: Breakup by Dosage Form (in %), 2024
Figure 6: Global: Hyperphosphatemia Drugs Market: Breakup by Distribution Channel (in %), 2024
Figure 7: Global: Hyperphosphatemia Drugs Market: Breakup by Region (in %), 2024
Figure 8: Global: Hyperphosphatemia Drugs (Sevelamer) Market: Sales Value (in Million USD), 2019 & 2024
Figure 9: Global: Hyperphosphatemia Drugs (Sevelamer) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 10: Global: Hyperphosphatemia Drugs (Calcium Based Phosphate Binders) Market: Sales Value (in Million USD), 2019 & 2024
Figure 11: Global: Hyperphosphatemia Drugs (Calcium Based Phosphate Binders) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 12: Global: Hyperphosphatemia Drugs (Iron Based Phosphate Binders) Market: Sales Value (in Million USD), 2019 & 2024
Figure 13: Global: Hyperphosphatemia Drugs (Iron Based Phosphate Binders) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 14: Global: Hyperphosphatemia Drugs (Lanthanum Carbonate) Market: Sales Value (in Million USD), 2019 & 2024
Figure 15: Global: Hyperphosphatemia Drugs (Lanthanum Carbonate) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 16: Global: Hyperphosphatemia Drugs (Other Products) Market: Sales Value (in Million USD), 2019 & 2024
Figure 17: Global: Hyperphosphatemia Drugs (Other Products) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 18: Global: Hyperphosphatemia Drugs (Tablets) Market: Sales Value (in Million USD), 2019 & 2024
Figure 19: Global: Hyperphosphatemia Drugs (Tablets) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 20: Global: Hyperphosphatemia Drugs (Syrups) Market: Sales Value (in Million USD), 2019 & 2024
Figure 21: Global: Hyperphosphatemia Drugs (Syrups) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 22: Global: Hyperphosphatemia Drugs (Capsules) Market: Sales Value (in Million USD), 2019 & 2024
Figure 23: Global: Hyperphosphatemia Drugs (Capsules) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 24: Global: Hyperphosphatemia Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 25: Global: Hyperphosphatemia Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 26: Global: Hyperphosphatemia Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 27: Global: Hyperphosphatemia Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 28: Global: Hyperphosphatemia Drugs (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 29: Global: Hyperphosphatemia Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 30: North America: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 31: North America: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 32: United States: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 33: United States: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 34: Canada: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 35: Canada: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 36: Asia-Pacific: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 37: Asia-Pacific: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 38: China: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 39: China: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 40: Japan: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 41: Japan: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 42: India: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 43: India: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 44: South Korea: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 45: South Korea: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 46: Australia: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 47: Australia: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 48: Indonesia: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 49: Indonesia: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 50: Others: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 51: Others: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 52: Europe: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 53: Europe: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 54: Germany: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 55: Germany: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 56: France: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 57: France: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 58: United Kingdom: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 59: United Kingdom: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 60: Italy: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 61: Italy: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 62: Spain: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 63: Spain: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 64: Russia: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 65: Russia: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 66: Others: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 67: Others: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 68: Latin America: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 69: Latin America: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 70: Brazil: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 71: Brazil: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 72: Mexico: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 73: Mexico: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 74: Others: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 75: Others: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 76: Middle East and Africa: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 77: Middle East and Africa: Hyperphosphatemia Drugs Market: Breakup by Country (in %), 2024
Figure 78: Middle East and Africa: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 79: Global: Hyperphosphatemia Drugs Industry: Drivers, Restraints, and Opportunities
Figure 80: Global: Hyperphosphatemia Drugs Industry: Value Chain Analysis
Figure 81: Global: Hyperphosphatemia Drugs Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Hyperphosphatemia Drugs Market: Key Industry Highlights, 2024 & 2033
Table 2: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Product (in Million USD), 2025-2033
Table 3: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Dosage Form (in Million USD), 2025-2033
Table 4: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
Table 5: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 6: Global: Hyperphosphatemia Drugs Market: Competitive Structure
Table 7: Global: Hyperphosphatemia Drugs Market: Key Players